Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the ...

The complete response letter (CRL) specifies that the current dosage duration of aflibercept is still safe but extending the ...

Long-term exposure to multiple air pollutants may silently wreak havoc on your gut, significantly increasing the risk of ...

The risk of some skin cancers, including squamous cell carcinoma, basal cell carcinoma, and non-melanoma skin cancer, was ...

A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) ...

Despite recent declines, health care worker burnout has not returned to prepandemic levels and remains a persistent concern ...

An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic ...

Panelists discuss how immunoglobulin A (IgA) nephropathy treatment has evolved to include supportive care with optimized blood pressure control and renin-angiotensin system blockade as first-line ...

Locke, MD, explains how cema-cel is genetically engineered for patient benefit. ALPHA [NCT03939026] and ALPHA2 [NCT04416984] are single-arm, multicenter, open-label phase 1 studies designed to test ...

Experts discuss whether providers should wait for another complete scientific statement from the National Lipid Association (NLA) or new guidelines from organizations like the American Heart ...

Experts discuss the cost of lipoprotein(a) (Lp[a]) tests and how these costs, along with the National Lipid Association’s (NLA) recommendation and supporting clinical evidence, may influence payer ...

Panelists discuss how immunoglobulin A (IgA) nephropathy significantly impacts patients’ quality of life through chronic symptoms, treatment burden, psychological effects, and the looming threat of ...